Ras farnesyltransferase: A new therapeutic target

Journal of Medicinal Chemistry

Volumn 40, Issue 19, 1997, Pages 2971-2990

  Leonard, Daniele M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ANTISENSE OLIGONUCLEOTIDE; BMS 186511; CINNAMIC ACID DERIVATIVE; FTI 275; GLIOTOXIN; L 745631; MANUMYCIN; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NATURAL PRODUCT; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL DESTRUCTION; CELL STRAIN 3T3; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE RAS; PRENYLATION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; AMINO ACID SEQUENCE; ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DRUG DESIGN; ENZYME INHIBITORS; GENES, RAS; GROWTH SUBSTANCES; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFERASES;

EID: 0030865773     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970226l     Document Type: Review

References (187)

1. Beck, L. A.; Hosick, T. J.; Sinensky, M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J. Cell. Biol. 1988, 707, 1307-1316.
2. Wolda, S. L.; Glomset, J. A. Evidence for modification of lamin B by a product of mevalonic acid. J. Biol. Chem. 1988, 263, 5997-6000.
3. Kamiya, Y.; Sakurai, A.; Tamura, S.; Takahashi, N. Structure of rhodotorucine A, a novel lipopeptide, inducing mating tube formation in Rhodosporidium toruloides. Biochem. Biophys. Res. Commun. 1978, 83, 1077-1083.
4. Ishibashi, Y.; Sakagami, Y.; Isogai, A.; Suzuki, A. Structures of tremerogens A-9291-I and A-9291-VIII: Peptidyl sex hormones of Tremella brasiliensis. Biochemistry 1984, 23, 1399-1404.
5. Brown, M. S.; Goldstein, J. L. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980, 21, 505-517.
6. Maltese, W. A.; Sheridan, K. M. Isoprenylated proteins in culture cells: Subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation. J. Cell Physiol. 1987, 133, 471-481.
7. Schmidt, R. A.; Schneider, C. J.; Glomset, J. A. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J. Biol. Chem. 1984, 259, 10175-10180.
8. Anderegg, R. J.; Betz, R.; Carr, S. A.; Crabb, J. W.; Duntze, W. Structure of Saccharomyces cerevisiae mating hormone a-factor. J. Biol. Chem. 1988, 263, 18236-18240.
9. Farnsworth, C. C.; Wolda, C. L.; Gelb, M. H.; Glomset, J. A. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem. 1989, 264, 20422-20429.
10. Casey, P. J.; Solski, P. A.; Der, C. J.; Buss, J. E. p21 Ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8323-8327.
11. Maltese, W. A.; Robishaw, J. D. Isoprenylation of C-terminal cysteine in a G-protein γ subunit. J. Biol. Chem. 1990, 265, 18071-18074.
12. Fukada, Y.; Takao, T.; Ohguro, H.; Yoshizawa, T.; Akino, T.; Shimonishi, Y. Farnesylated γ-subunit of photoreceptor G protein indispensable for GTP-binding. Nature (London) 1990, 346, 658-660.
13. Lai, R. K.; Perez-Sala, D.; Canada, F. J.; Rando, R. R. The γ-subunit of transducin is farnesylated. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7673-7677.
14. Chow, M.; Der, C. J.; Buss, J. E. Structure and biological effects of lipid modifications on proteins. Curr. Opinion Cell Biol. 1992, 4, 629-636.
15. Hancock, J. F.; Magee, A. I.; Chilad, J. E.; Marshall, C. J. All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57, 1167-1177.
16. Schafer, W. R.; Kim, R.; Sterne, R.; Thorner, J.; Kim, S.-H.; Rine, J. Genetic and pharmacological suppression of oncogenic mutations in Ras genes of yeast and humans. Science 1989, 245, 379-385.
17. Lowy, D. R.; Willumsen, B. M. Function and regulation of Ras. Annu. Rev. Biochem. 1993, 62, 851-891.
18. Barbacid, M. Ras genes. Anna. Rev. Biochem. 1987, 56, 779-827.
19. DeFeo, D.; Gonda, M. A.; Young, H. A.; Chang, E. H.; Lowy, D. R.; Scolnick, E. M.; Ellis, R. W. Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 3328-3332.
20. Ellis, R. W.; DeFeo, D.; Shih, T. Y.; Gonda, M. A.; Young, H. A.; Tsuchida, N.; Lowy, D. R.; Scolnick, E. M. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (London) 1981, 292, 506-511.
21. Parada, L. F.; Tabin, C. J.; Shih, C.; Weinberg, R. A. Human EJ bladder carcinoma oncogenesis homolog of Harvey sarcoma virus Ras gene. Nature (London) 1982, 297, 474-478.
22. Santos, E.; Tronick, S. R.; Aaronson, S. A.; Pulciani, S.; Barbacid, M. T24 human bladder carcinoma oncogene is an activated form of the normal human homolog of BALB- and Harvey-MSV transforming gene. Nature (London) 1982, 298, 343-347.
23. Der, C. J.; Kronitris, T. G.; Cooper, G. M. Transfoming genes of human bladder and lung carcinoma cell lines are homologous to the Ras genes of Harvey and Kirsten sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 3637-3640.
24. Shimizu, K.; Goldfarb, M.; Perucho, M.; Wigler, M. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 383-387.
25. Hall, A.; Marshall, C. J.; Spurr, N. K.; Weiss, R. A. Identification of transforming gene in two human sarcoma cell lines as a new member of the Ras gene family located on chromosome 1. Nature (London) 1983, 303, 396-400.
26. Miyoshi, J.; Kagimoto, M.; Soeda, E.; Sakaki, Y. The human c-Ha-Ras 2 is a processed pseudogene inactivated by numerous base substitutions. Nucleic Acid Res. 1984, 12, 1821-1828.
27. McGrath, J. P.; Capon, D. J.; Smith, D. H.; Chen, E. Y.; Seeburg, P. H.; Goeddel, D. Y.; Levinson, A. D. Structure and organization of the human Ki-Ras proto-oncogene and a related processed pseudogene. Nature (London) 1983, 304, 501-506.
28. Pulciani, S.; Santos, E.; Lauver, A. V.; Long, L. K.; Robbins, K. C.; Barbacid, M. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 2845-2849.
29. Goldfarb, M.; Shimizu, K.; Perucho, M.; Wigler, M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature (London) 1982, 296, 404-409.
30. Shih, C.; Weinberg, R. A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982, 29, 161-169.
31. Capon, D. J.; Chen, E. Y.; Levinson, A. D.; Seeburg, P. H.; Goeddel, D. Y. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homolog. Nature (London) 1983, 302, 33-37.
32. Reddy, E. P. Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene. Science 1983, 220, 1061-1063.
33. Shimizu, K.; Birnbaum, D.; Ruley, M. A.; Fasano, O.; Suard, Y.; Edlund, L.; Taparowski, E.; Goldfarb, M.; Wigler, M. Structure of the Ki-Ras gene of the human lung carcinoma cell line Calu1. Nature (London) 1983, 304, 497-500.
34. Nakano, H.; Yamamoto, F.; Neville, C.; Evans, D.; Mizuno, T.; Perucho, M. Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-Ras oncogenes. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 71-75.
35. Taparowsky, E.; Shimizu, K.; Goldfarb, M.; Wigler, M. Structure and activation of the human N-Ras-gene. Cell 1983, 34, 581-586.
36. Brown, R.; Marshall, C. J.; Pennie, S. G.; Hall, A. Mechanism of activation of an N-Ras gene in the human fibrosarcoma cell line HT 1080. EMBO J. 1984, 3, 1321-1326.
37. Shih, T. Y.; Weeks, M. O.; Young, H. A.; Scolnick, E. M. Identification of a sarcoma virus-coded phosphoprotein in non producer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology 1979, 96, 64-79.
38. Willumsen, B. M.; Christensen, A.; Hubert, N. L.; Papageorge, A. G.; Lowy, D. R. The p21 Ras C-terminus is required for transformation and membrane association. Nature (London) 1984, 310, 583-586.
39. Ashby, M. N.; King, D. S.; Rine, J. Endoproteolytic processing of a farnesylated peptide in vitro. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4613-4617.
40. Ma, Y.-T.; Rando, R. R. A microsomal endoprotease that specifically cleaves isoprenylated peptides. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6275-6279.
41. Akopyan, T. N.; Couedel, Y.; Beaumont, A.; Fournie-Zaluski, M.-C.; Roques, B. P. Cleavage of farnesylated COOH-terminal heptapeptide of mouse N-Ras by brain microsomal membranes: Evidence for a carboxypeptidase which specifically removes the COOH-terminal methionine. Biochem. Biophys. Res. Commun. 1992, 187, 1336-1342.
42. Clarke, S.; Vogel, J. P.; Deschenes, R. J.; Stock, J. Posttranslational modification of the Ha-Ras oncogene protein: Evidence for a third class of protein carboxyl methyltransferases. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4643-4646.
43. Perez-Sala, D.; Tan, E. W.; Canada, F. J.; Rando, R. R. Methylation and demethylation reactions of guanine nucleotide-binding proteins of retinal rod outer segments. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 3043-3046.
44. Dudler, T.; Gelb, M. H. Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. J. Biol. Chem. 1996, 271, 11541-11547.
45. Liu, L.; Dudler, T.; Gelb, M. H. Purification of a protein palmitoyltransferase that acts on H-Ras protein and on C- terminal N-Ras peptide. J. Biol. Chem. 1996, 271, 23269-23276.
46. Ghomashchi, F.; Zhang, X.; Liu, L.; Gelb, M. Binding of prenylated and polybasic peptides to membranes: affinities and intervesicle exchange. Biochemistry 1995, 34, 11910-11918.
47. Bourne, H. R.; Sanders, D. A.; McCormick, F. The GTPase super-family: A conserved switch for diverse cell functions. Nature (London) 1990, 348, 125-132.
48. Bourne, H. R.; Sanders, D. A.; McCormick, F. The GTPase super-family: Conserved structure and molecular mechanism. Nature (London) 1990, 349, 117-127.
49. Cox, A. D.; Der, C. J. The Ras/cholesterol connection: Implications for Ras oncogenicity. Crit. Rev. Oncog. 1992, 3, 365-400.
50. Tabin, C. J.; Bradley, S. M.; Bargmann, C. I.; Weinberg, R. A.; Papageorge, A. L.; Scolnick, E. M.; Dhar, R.; Lowy, D. R.; Chang, E. H. Mechanism of activation of human oncogne. Nature (London) 1982, 300, 143-149.
51. Reddy, E. P.; Reynolds, R. K.; Santos, E.; Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24-human bladder carcinoma oncogene. Nature (London) 1982, 300, 149-152.
52. Taparowsky, E.; Suard, Y.; Fasano, O.; Shimizu, K.; Goldfarb, M.; Wigler, M. Activation of the T24-bladder carcinoma transforming gene is linked to a single amino acid change. Nature (London) 1982, 300, 762-765.
53. Bos, J. L.; Toksoz, D.; Marshall, C. J.; Verlaan de Vries, M.; Veeneman, G. H.; van der Eb, A. J.; van Boom, J. H.; Janssen, J. W. G.; Steenvoorden, A. C. M. Amino acid substitutions at codon 13 of the N-Ras oncogene in human acute myeloid leukemia. Nature (London) 1985, 315, 726-730.
54. Dhar, R.; Ellis, R. W.; Shih, T. Y.; Oroszlan, S.; Shapiro, B.; Maizee, J.; Lowy, D.; Scolnick, E. Nucleotide sequence of the p21 transforming protein of Harvey murine sarcoma virus. Science 1982, 217, 934-936.
55. Tsuchida, N.; Ohtsubo, E.; Ryder, T. Nucleotide sequence of the oncogene encoding the p21 transforming protein of Kirsten murine sarcoma virus. Science 1982, 217, 937-939.
56. Yuasa, Y.; Srivastava, S. K.; Dunn, C. Y.; Rhim, J. S.; Reddy, E. P.; Aaronson, S. A. Acquisition of transforming properties by alternative point mutation within c-bas/has human protooncogene. Nature (London) 1983, 303, 775-779.
57. Yamamoto, F.; Perucho, M. Activation of a human c-K-Ras oncogene. Nucleic Acid Res. 1984, 12, 8873-8885.
58. Abrams, S. I.; Hand, P. H.; Tsang, K. Y.; Schlom, J. Mutant Ras epitopes as targets for cancer vaccines. Semin. Oncol. 1996, 23, 118-134.
59. Klares, H.; Spandidos, D. A. Mutations of Ras genes in human tumours. Int. J. Oncol. 1995, 7, 413-421.
60. Keohavong, P.; DeMichele, M. A.; Melacrinos, A. C.; Landreneau, R. J.; Weyant, R. J.; Siegfried, J. M. Detection of K-Ras in lung carcinomas: Relationship to prognosis. Clin. Cancer Res. 1996, 2, 411-418.
61. Sepp-Lorenzino, L.; Ma, Z.; Rands, E.; Kohl, N. E.; Gibbs, J. B.; Oliff, A.; Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell Unes. Cancer Res. 1995, 55, 5302-5309.
62. Valencia, A.; Chardin, P.; Wittinghofer, A.; Sandor, C. The Ras protein family: evolutionary tree and role of conserved amino acids. Biochemistry 1991, 30, 4637-4648.
63. Kahn, R. A.; Der, C. J.; Bokoch, G. M. The Ras superfamily of GTP-binding proteins: guidelines on nomenclature. FASEB J. 1992, 6, 2512-2513.
64. 1) with remote similarity to the Ras-related GTPases. J. Biol. Chem. 1995, 270, 28982-28988.
65. Macara, I. G.; Lounsbury, K. M.; Richards, S. A.; McKiernan, C.; Bar-Sage, D. The Ras-superfamily of GTPases. FASEB J. 1996, 10, 625-630.
66. Scheffzek, K.; Klebe, C.; Frits-Wolf, K.; Kabasch, W.; Wittinghofer, A. Crystal structure of the nuclear Ras-related protein Ran in its GDP-bound form. Nature 1995, 374, 378-381.
67. Boguski, M. S.; McCormick, F. Proteins regulating Ras and its relatives. Nature 1993, 366, 643-654.
68. Spaargaren, M.; Bischoff, J. R.; McCormick, F. Signal transduction by Ras-like GTPases: A potential target for anticancer drugs. Gene Expression 1995, 4, 345-356.
69. Stokoe, D.; Macdonald, S. G.; Cadwallader, K.; Symons, M.; Hancock, H. F. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994, 264, 1463-1467.
70. Leevers, S. J.; Paterson, H. F.; Marshall, C. J. Requirement of Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (London) 1994, 369, 411-414.
71. Burgering, B. M. T.; Bos, J. L. Regulation of Ras-mediated signaling; more than one way to skin a cat. TiBS 1995, 20, 18-22.
72. Mulder, K. M.; Morris, S. L. Activation of p21Ras by transforming growth factor-beta in epithelial cells. J. Biol. Chem. 1992, 267, 5029-5031.
73. 1 growth arrest by transforming growth factor β1 requires cellular Ras activity. J. Biol. Chem. 1993, 268, 21448-21452.
74. Duronio, V.; Welham, M. J.; Abraham, S.; Dryden, P.; Schrader, J. W. p21Ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21Ras GTPase-activating protein. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 1587-1591.
75. van Corven, E. J.; Hordijk, P. L.; Medema, R. H.; Bos, J. L.; Moolenaar, W. H. Pertussis toxin-sensitive activation of p2l-(Ras) by G-protein coupled receptor agonists in fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1257-1261.
76. Sadoshima, J.; Izumo, S. Angiotensin II activates p21 Ras by tyrosine kinase and protein kinase c-dependent mechanism in cardiac myocytes. Circulation 1993, 88, Abstract I-334.
77. Kikuchi, A.; Demo, S. D.; Ye, Z.-H.; Chen, Y.-W.; Williams, L. RalGDS family members interact with the effector loop of Ras p21. Mol. Cell Biol. 1994, 14, 7483-7491.
78. Hofer, F.; Fields, S.; Schneider, C.; Martin, G. S. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11089-11093.
79. Spaargaren, M.; Bischoff, J. R. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-Ras, H-Ras, K-Ras and Rap. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12609-12613.
80. Rodriguez-Viciana, P.; Warne, P. H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M. J.; Waterfield, M. D.; Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (London) 1994, 370, 527-532.
81. Diaz-Meco, M. T.; Lozano, J.; Municio, M. M.; Berra, E.; Frutos, S.; Sanz, L.; Moscat, J. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C ζ. J. Biol. Chem. 1994, 269, 31706-31716.
82. Han, L.; Colicelli, J. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf-1. Mol. Cell Biol. 1995, 15, 1318-1323.
83. McCormick, F. Ras biology in atomic detail. Nature Struct. Biol. 1996, 3, 653-655.
84. Joneson, T.; White, M. A.; Wigler, M. H.; Bar-Sagi, D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of Ras. Science 1996, 271, 810-812.
85. Ridley, A.; Paterson, H. F.; Johnston, C. L.; Diekmann, D.; Hall, A. The small GTP-binding protein Rae regulates growth-factor induced membrane ruffling. Cell 1992, 70, 401-410.
86. Clarke, S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem. 1992, 61, 355-386.
87. Cox, A. D.; Der, C. J. Protein prenylation: more than just glue? Curr. Opin. Cell Biol. 1992, 4, 1008-1016.
88. Pai, E. F.; Kabsch, W.; Krengel, U.; Holmes, K. C.; John, J.; Wittinghofer, A. Structure of the guanine-nucleotide-binding domain of the Ha-Ras oncogene product p21 in the triphosphate conformation Nature 1989, 341, 209-214.
89. Milburn, M. V.; Tong, L.; DeVos, A. M.; Bruenger, A.; Yamaizumi, Z.; Nishimura, S.; Kim, S.-H. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic Ras proteins. Science 1990, 247, 939-945.
90. Jurnak, F.; Heffron, S.; Bergmann, E. Conformational changes involved in the activation of Ras p21: implications for related proteins. Cell 1990, 60, 525-528.
91. Sigal, I. S.; Gibbs, J. B.; D'Alonzo, J. S.; Scolnick, E. M. Identification of effector residues and a neutralizing epitope of Ha-Ras-encoded p21. Proc. Natl Acad. Sci. U.S.A. 1986, 83, 4725-4729.
92. Hwang, M.-C. C.; Sung, Y.-J.; Hwang, Y.-W. The differential effects of the Gly-60 to Ala mutation on the interaction of H-Ras p21 with different downstream targets. J. Biol. Chem. 1996, 271, 8196-8202.
93. Farnsworth, C. L.; Feig, L. A. Dominant inhibitory mutations in the Mg+2-binding site of Ras-H prevent its activation by GTP. Mol. Cell Biol. 1991, 11, 4822-4829.
94. Yamasaki, K.; Shirouzu, M.; Muto, Y.; Fujita-Yoshigaki, J.; Koide, H.; Ito, Y.; Kawai, G.; Hattori, S.; Yokoyama, S.; Nishimura, S.; Miyazawa, T. Site-directed mutagenesis, fluorescence and two dimensional NMR studies on microenvironments of effector region aromatic residues of humanc-Ha-Ras protein. Biochemistry 1994, 33, 65-73.
95. Sigal, I. S.; Marshall, M. S.; Schaber, M. D.; Vogel, U. S.; Scolnick, E. M.; Gibbs, J. B. Structure/function studies of the Ras protein. Cold Spring Harbor Symp. Quant. Biol. 1988, 53, 863-869.
96. Moomaw, J. F.; Casey, P. J. Mammalian protein geranylgeranyltransferase. Subunit composition and metal requirements. J. Biol. Chem. 1992, 267, 17438-17443.
97. Reiss, Y.; Brown, M. S.; Goldstein, J. L. Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltranferase from rat brain, a zinc metalloenzyme. J. Biol. Chem. 1992, 267, 6403-6408.
98. James, G. L.; Goldstein, J. L.; Brown, M. S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 1995, 270, 6221-6226.
99. Vogt, A.; Sun, J.; Qian, Y.; Tan-Chiu, E.; Hamilton, A. D.; Sebti, S. M. Burkitt lymphoma Daudi cells contain two distinct FTases with different divalent cation requirements. Biochemsitry 1995, 34, 12398-12403.
100. Manne, V.; Roberts, D.; Tobin, A.; O'Rourke, E.; DeVirgilio, M.; Meyers, C.; Ahmed, N.; Kurz, B.; Resh, M.; Kung, H.-F.; Barbacid, M. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7541-7545.
101. Schaber, M. D.; O'Hara, M. B.; Garsky, V. M.; Mosser, S. D.; Bergstrom, J. D.; Moores, S. L.; Marshall, M. S.; Friedman, P. A.; Dixon, R. A. F.; Gibbs, J. B. Polyisoprenylation of Ras in vitro by a farnesyl-protein-transferase. J. Biol. Chem. 1990, 265, 14701-14704.
102. Reiss, Y.; Seabra, M. C.; Goldstein, J. L.; Brown, M. S. Purification of Ras farnesyl: protein transferase. Methods: A Companion to Methods in Enzymology 1990, 1, 241-245.
103. Reiss, Y.; Goldstein, J. L.; Seabra, M. C.; Casey, P. J.; Brown, M. S. Inhibition of purified p21 Ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990, 62, 81-88.
104. Omer, C. A.; Kral, A. M.; Diehl, R. E.; Prendergast, G. C.; Powers, S.; Allen, C. M.; Gibbs, J. B.; Kohl, N. E. Characterization of recombinant human farnesyl-protein transferase: Cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry 1993, 32, 5167-5176.
105. Casey, P. J.; Thissen, J. A.; Moomaw, J. F. Enzymatic modification of protein with a geranylgeranyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8631-8635.
106. Yokoyama, K.; Goodwin, G.; Ghomashchi, F.; Glomset, J. A.; Gelb, M. H. A protein geranylgeranyltransferase from bovine brain: Implications for protein prenylation specificity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 5302-5306.
107. Reiss, Y.; Seabra, M. C.; Armstrong, S. A.; Slaughter, C. A.; Goldstein, J. L.; Brown, M. S. Non identical subunit of p21 H-Ras farnesyl transferase: peptide binding and farnesyl pyrophosphate carrier functions, J. Biol. Chem. 1991, 266,10672-10677.
108. Park, H. W.; Boduluri, S. R.; Moomaw, J. F.; Casey, P. J.; Beese, L. S. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997, 274, 1800-1804.
109. Boyartchuk, V. L.; Ashby, M. N.; Rine, J. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 1997, 275, 1796-1800.
110. Stephenson, R. C.; Clarke, S. Identification of a C-terminal protein carboxyl methyltransferase in rat liver membranes utilizing a synthetic farnesyl cysteine-containing peptide substrate. J. Biol. Chem. 1990, 265, 16248-16254.
111. Pillinger, M. H.; Volker, C.; Stock, J. B.; Weissmann, G.; Philips, M. R. Characterization of a plasma membrane-associated prenylcysteine-directed α-carboxyl methyltransferase in human neutrophils. J. Biol. Chem. 1994, 269, 1486-1492.
112. Volker, C.; Lane, P.; Kwee, C.; Johnson, M.; Stock, J. A single activity carboxyl methylates both farnesyl and geranylgeranyl cysteine residues. FEBS Lett. 1991, 295, 189-194.
113. Perez-Sala, D.; Gilbert, B. A.; Tan, E. W.; Rando, R. R. Prenylated protein methyltransferases do not distinguish between farnesylated and geranylgeranylated substrates. Biochem. J. 1992, 284, 835-840.
114. Volker, C.; Miller, R. A.; McClearym, W. R.; Rao, A.; Poenie, M.; Backer, J. M.; Stock, J. B. Effects of farnesyl cysteine analogs on protein carboxyl methylation and signal transduction. J. Biol. Chem. 1991, 266, 21515-21522.
115. Gilbert, B. A.; Tan, E. W.; Perez-Sala, D.; Rando, R. R. Structure-activity studies on the retinal rod outer segment isoprenylated protein methyltransferase. J. Am. Chem. Soc. 1992, 114, 3966-3973.
116. Goldstein, J. L.; Brown, M. S.; Stradley, S. J.; Reiss, Y.; Gierasch, L. M. Non farnesylated tetrapeptide inhibitors of protein farnesyltransferase, J. Biol. Chem. 1991, 266, 15575-15578.
117. Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Giuliani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260, 1934-1937.
118. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deana, A. A.; Garsky, V. M.; Scholz, T. H.; Gibbs, J. B.; Smith, R. L. Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J. Med. Chem. 1994, 37, 725-732.
119. Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; deSolms, S. J.; Conner, M. W.; Anthony, N. J.; Holtz, W. J.; Gomez, R. P.; Lee, T.-J.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein farnesyltransferase inhibitors block the growth of Ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141-9145.
120. Prendergast, G. C.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyl-transferase inhibition causes morphological reversion of Ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell Biol. 1994, 14, 4193-4202.
121. Hall, A. Ras-related GTPases and the cytoskeleton. Mol. Cell Biol. 1992, 3, 475-479.
122. Adamson, P.; Marshall, C. J.; Hall, A.; Tilbrook, P. A. Posttranslational modification of p21Rho proteins. J. Biol. Chem. 1992, 267, 20033-20038.
123. Lebowitz, P. F.; Davide, J. P.; Prendergast, G. C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell Biol. 1995, 15, 6613-6622.
124. Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P.; deSolms, S. J.; Giuliani, E. A.; Gomez, R. P.; Graham, S. L.; Hamilton, K.; Handt, L. K.; Hartman, G. D.; Koblan, K. S.; Kral, A. M.; Miller, P. J.; Mosser, S. D.; O'Neill, T. J.; Rands, E.; Schaber, M. D.; Gibbs, J. B.; Oliff, A. Inhibition of farnesyl-transferase induces regression of mammary and salivary carcinomas in Ras transgenic mice. Nature Medicine 1995, 1, 792-797.
125. Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J. J.; Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 1993, 268, 18415-18418.
126. Cox, A. D.; Garcia, A. M.; Westwick, J. K.; Kowalczyk, J. J.; Lewis, M. D.; Brenner, D. A.; Der, C. J. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. J. Biol. Chem. 1994, 269, 19203-19206.
127. Nagasu, T.; Yoshimatsu, K.; Rowell, C.; Lewis, M. D.; Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995, 55, 5310-5314.
128. Leftheris, K.; Kline, T.; Kite, G. D.; Cho, Y. H.; Bhide, R. S.; Patel, D. V.; Patel, M. M.; Schmidt, R. J.; Weller, H. N.; Andahazy, M. L.; Carboni, J. M.; Gullo-Brown, J. L.; Lee, F. Y. F.; Ricca, C.; Rose, W. C.; Yan, N.; Barbacid, M.; Hunt, J. T.; Meyers, C. A.; Seizinger, B. R.; Zahler, R.; Manne, V. Development of highly potent inhibitors of Ras farnesyl transferase possessing cellular and in vivo activity. J. Med. Chem. 1996, 39, 224-236.
129. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, cell active, nonthiol tetrapeptide inhibitors of farnesyl tranferase. J. Med. Chem. 1906, 39, 353-358.
130. James, G. L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras famesylation in animal cells. Science 1993, 260, 1937-1942.
131. James, G. L.; Brown, M. S.; Cobb, M. H.; Goldstein, J. L. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed rat-1 cells, but not in untransformed cells. J. Biol. Chem. 1994, 269, 27705-27714.
132. Dalton, M. B.; Fantle, K. S.; Bechtold, H. A.; DeMaio, L.; Evans, R. M.; Krystosek, A.; Sinensky, M. The farnesyl protein transferase inhibitor BZA-5B blocks famesylation of nuclear lamins and p21 Ras but does not affect their function or localization. Cancer Res. 1995, 55, 3295-3304.
133. 2X peptidomimetics. J. Biol. Chem. 1993, 268, 20695-20698.
134. Qian, Y.; Blaskovich, M. A.; Saleem, M.; Seong, C. M.; Wathen, S. P.; Hamilton, A. D.; Sebti, S. M. Design and structural requirements of potent peptidomimetic inhibitors of p21 Ras farnesyltransferase. J. Biol. Chem. 1994, 269, 12410-12413.
135. Qian, Y.; Blaskovich, M. A.; Seong, C.-M.; Vogt, A.; Hamilton, A. D.; Sebti, S. M. Peptidomimetic inhibitors of p21 Ras farnesyl transferase: Hydrophobic functionalization leads to disruption of p21 Ras membrane association in whole cells. BioOrg. Med. Chem. Lett. 1994, 4, 2579-2584.
136. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 1995, 270, 26802-26806.
137. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 1995, 55, 4243-4247.
138. Vogt, A.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Hamilton, A. D.; Sebti, S. M. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem, 1995, 270, 660-664.
139. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyl transferase inhibitors. J. Med. Chem. 1996, 39, 217-223.
140. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Chen, I.-W.; Koblan, K. S.; Kohl, N. E.; Omer, C. A.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Lin, J. H.; Smith, R. L.; Oliff, A. Design and biological activity of a series of small, low molecular weight farnesyl protein transferase inhibitors. Proc. Am. Assoc. Cancer Res. 1995, 36, Abstract 2612.
141. Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Bock, R. L.; Conner, M. W.; Davide, J. P.; Hamilton, K.; Koblan, K. S.; Kohl, N. E.; Kral, A. M.; Mosser, S. D.; Omer, C. A.; Pompliano, D. L.; Rands, E.; Schaber, M. D.; Shah, D.; Wilson, F. R.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Smith, R. L. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, noncarboxylic acid inhibitors of farnesyl transferase. J. Med. Chem. 1996, 39, 1345-1348.
142. Stradley, S. J.; Rizo, J.; Gierasch, L. M. Conformation of a heptapeptide substrate bound to protein farnesyltransferase. Biochemistry 1993, 32, 12586-12590.
143. Bukhtiyarov, Y. E.; Omer, C. A.; Allen, C. M. Photoreactive analogues of prenyl diphosphates as inhibitors and probes of human protein farnesyl transferase and geranylgeranyl transferase type I. J. Biol. Chem. 1995, 270, 19035-19040.
144. Yokoyama, K.; McGeady, P.; Gelb, M. H. Mammalian protein geranylgeranyl transferase-I: Substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. Biochemistry 1995, 34, 1344-1354.
145. Pompliano, D. L.; Rands, E.; Schaber, M. D.; Mosser, S. D.; Anthony, N. J.; Gibbs, J. B. Steady-state kinetic mechanism of Ras farnesyl:protein transferase. Biochemistry 1992, 37, 3800-3807.
146. Gibbs, J. B.; Pompliano, D. L.; Mosser, S. D.; Rands, E.; Lingham, R. B.; Singh, S. B.; Scolnick, E. M.; Kohl, N. E.; Oliff, A Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J. Biol. Chem. 1993, 268, 7617-7620.
147. Manne, V.; Ricca, C. S.; Brown, J. G.; Tuomari, A. V.; Yan, N.; Patel, D.; Schmidt, R.; Lynch, M. J.; Ciosek, C. P., Jr.; Carboni, J. M.; Robinson, S.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R.; Biller, S. A. Ras farnesylation as a target for novel antiturnor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev. Res. 1995, 34, 121-137.
148. Kang, M. S.; Stemerick, D. M.; Zwolshen, J. H.; Harry, B. S.; Sunkara, P. S.; Harrison, B. L. Farnesyl-derived inhibitors of Ras farnesyl transferase. Biochem. Biophys. Res. Commun. 1995, 217, 245-249.
149. Lamothe, M.; Perrin, D.; Blotiere, D.; Leborgne, M.; Gras, S.; Bonnet, D.; Hill, B. T.; Halazy, S. Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine. BioOrg. Med. Chem. Lett. 1996, 6, 1291-1296.
150. Bhide, R. S.; Patel, D. V.; Patel, M. M.; Robinson, S. P.; Hunihan, L. W.; Gordon, E. M. Rational design of potent carboxylic acid based bisubstrate inhibitors of Ras farnesyl protein transferase. BioOrg. Med. Chem. Lett. 1994, 4, 2107-2112.
151. Manne, V.; Yan, N.; Carboni, J. M.; Tuomari, A. V.; Ricca, C. S.; Brown, J. G.; Andahazy, M. L.; Schmidt, R. J.; Patel, D.; Zahler, R.; Weinmann, R.; Der, C. J.; Cox, A. D.; Hunt, J. T.; Barbacid, M.; Seizinger, B. R. Bisubstrate inhibitors of farnesyl transferase: A novel class of specific inhibitors of Ras transformed cell. Oncogene 1995, 10, 1763-1779.
152. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Goetz, M. A.; Jenkins, R. G.; Nallin-Omstead, M.; Silverman, K. C.; Bills, G. F.; Mosley, R. T.; Gibbs, J. B.; Albers-Schonberg, G.; Ungham, R. B. Isolation and structure of chaetomellic acids A and B from Chaetomella acutiseta: Farnesyl pyrophoshate mimic inhibitors of Ras farnesyl-protein transferase. Tetrahedron 1993, 49, 5917-5926.
153. Singh, S. B. Synthesis of chaetomellic acid A:A potent inhibitor of Ras farnesyl-protein transferase. Tetrahedon Lett. 1993, 34, 6521-6524.
154. Lingham, R. B.; Silverman, K. C.; Bills, G. F.; Cascales, C.; Sanchez, M.; Jenkins, R. G.; Gratner, S. E.; Martin, I.; Diez, M. T.; Pelaez, P.; Mochales, S.; Kong, Y.-L.; Burg, R. W.; Meinz, M. S.; Huang, L.; Nallin-Omstead, M.; Mosser, S. D.; Schaber, M.; Omer, C. A.; Pompliano, D. L.; Gibbs, J. B.; Singh, S. B. Chaetomella acutiseta produces chaetomellic acids A and B which are reversible inhibitors of farnesyl-protein transferase. Appl. Microbiol. Biotechnol. 1993, 40, 370-374.
155. Singh, S. B.; Liesch, J. M.; Lingham, R. B.; Goetz, M. A.; Gibbs, J. B. Actinoplanic acid A: A macrocyclic polycarboxylic acid which is a potent inhibitor of Ras farnesyl-protein transferase. J. Am. Chem. Soc. 1994, 116, 11606-11607.
156. Hara, M.; Akasaka, K.; Akinaga, S.; Okabe, M.; Nakano, H.; Gomez, R.; Wood, D.; Uh, M.; Tamanoi, F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2281-2285.
157. Tamanoi, F. Inhibition of Ras farnesyltransferase. Trends Biochem. Sci. 1993, 18, 349-353.
158. Shiomi, K.; Yang, H.; Inokoshi, J.; Van Der Pyl, D.; Nakagawa, A.; Takeshima, H.; Omura, S. Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. II. Structural elucidation of pepticinnamin E. J. Antiobiot. 1993, 46, 229-234.
159. Singh, S. B.; Jones, E. T.; Goetz, M. A.; Bills, G. F.; Nallin-Omstead, M.; Jenkins, R. G.; Lingham, R. B.; Silverman, K. C.; Gibbs, J. B. Fusidienol: A novel inhibitor of Ras farnesyl-protein transferase from Fusidium griseum. Tetrahedron Lett. 1994, 35, 4963-4696.
160. Singh, S. B.; Zink, D. L.; Liesch, J. M.; Ball, R. G.; Goetz, M. A.;
161. Van der Pyl, D.; Inokoshi, J.; Shiomi, K.; Yang, H.; Takeshima, H.; Omura, S. Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin. J. Antibiot. 1992, 45, 1802-1805.
162. Liu, W. C.; Barbacid, M.; Bulgar, M.; Clark, J. M.; Croswell, A. R.; Dean, L.; Doyle, T. W.; Fernandes, P. B.; Huang, S.; Manne, V.; Pirnik, D. M.; Wells, J. S.; Meyers, E. 10′-Desmethoxystreptonigrin, a novel analog of streptonigrin. J. Antibiot. 1992, 45, 454-457.
163. Singh, S. B.; Zink, D. L.; Bills, G. F.; Jenkins, R. G.; Silverman, K. C.; Lingham, R. B. Cylindrol A: A novel inhibitor of Ras farnesyl-protein transferase from Cylindrocarpon lucidum. Tetrahedron Lett. 1995, 36, 4935-4938.
164. Leonard, D. M.; Shuler, K. R.; Poulter, C. J.; Eaton, S. R.; Sawyer, T. K.; Hodges, J. C.; Su, T.-Z.; Scholten, J. D.; Gowan, R.; Sebolt-Leopold, J. S.; Doherty, A. M. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit Ras farnesyltransferase. J. Med. Chem. 1997, 40, 192-200.
165. Scholten, J. D.; Zimmerman, K.; Oxender, M.; Sebolt-Leopold, J.; Gowan, R.; Leonard, D.; Hupe, D. J. Inhibitors of farnesyl: protein transferase: A possible cancer chemotherapeutic. BioOrg. Med. Chem. Lett. 1996, 4, 1537-1543.
166. Bolton, G. L.; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. The SAR of tripeptide inhibitors of Ras farnesylprotein transferase. Presented at the 209th National Meeting of the American Chemical Society, Anaheim, CA, April 1995; MEDI 032.
167. Bolton, G. L.; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. Modified peptide inhibitors of Ras farnesylprotein transferase. Presented at the 209th National Meeting of the American Chemical Society, Anaheim, CA, April 1995; MEDI 033.
168. Shuler, K. R.; Leonard, D. M.; Bolton, G. L.; Scholten, J.; Sebolt-Leopold, J.; Doherty, A. M. The inhibition of Ras farnesyl transferase by a modified dipeptide: Structure-activity relation-ships. Presented at the 211th National Meeting of the American Chemical Society, New Orleans, LA, April 1996; MEDI 086.
169. Bolton, G. L; Creswell, M. W.; Hodges, J. C.; Gowan, R. C.; Scholten, J.; Sebolt-Leopold, J. S. Modified dipeptide inhibitors of Ras farnesyl transferase. Presented at the 25th National Medicinal Chemistry Symposium, Ann Arbor, MI, June 1996.
170. Leonard, D. M.; Shuler, K. R.; McNamara, D.; Bur, S.; Dobrusin, E. M.; Bolton, G. L.; Scholten, J.; Zimmerman, K.; Sebolt-Leopold, J. S.; Gowan, R. C.; Latash, M.; Przybranowski, S.; Leopold, W. R.; Doherty, A. M. Design of peptidomimetic Ras farnesyl transferase inhibitors from a pentapeptide lead. Presented at the 24th European Peptide Symposium, Edinburgh, Scotland, September 1996.
171. Gowan, R. C.; Ferguson, D.; Hook, K.; Przybranowski, S.; Elliott, W. L.; Leopold, W. R.; Scholten, J.; Bolton, G. L.; Hodges, J. C.; Sebolt-Leopold, J. S. Inhibition of Ras farnesyl protein transferase by a series of substituted thiosulfuric acids. Proc. Am. Assoc. Cancer Res. 1995, 36, Abstract 2562.
172. Bishop, W. R.; Bond, R.; Petrin, J.; Wang, L.; Patton, R.; Doll, R.; Njorogi, G.; Catino, J.; Schwartz, J.; Windsor, W.; Syto, R.; Schwartz, J.; Carr, D.; James, L.; Kirschmeier, P. Novel tricyclic inhibitor of farnesyl protein transferase: Biochemical characterization and inhibition of Ras modification in transfected cos cells. J. Biol Chem. 1995, 270, 30611-30618.
173. Scwab, G.; Chavany, C.; Duroux, I.; Goubin, G.; Lebeau, J.; Helene, C.; Saison-Behmoaras, T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-Ras-mediated cell proliferation and tumorigenecity in nude mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10460-10464.
174. Monia, B. P.; Johnston, J. F.; Geiger, T.; Muller, M.; Fabbro, D. Antitumor activity of a phosphotothioate antisense oligodeoxy-nucleotide targeted against c-Raf kinase. Nature Medicine 1996, 2, 668-674.
175. Chan, A. M.-L.; Miki, T.; Meyers, K. A.; Aaronson, S. A. A human oncogene of the Ras superfamily unmasked by expression cDNA cloning. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7558-7562.
176. Graham, S. M.; Cox, A. D.; Drivas, G.; Rush, M. G.; D'Eustachio, P.; Der, C. J. Aberrant function of the Ras-related protein TC21/ R-Ras2 triggers malignant transformation. Mol. Cell. Biol. 1995, 14, 4108-4115.
177. Carboni, J. M.; Van, N.; Cox, A. D.; Bustelo, X.; Graham, S. M.; Lynch, M. J.; Weinmann, R.; Seizinger, B. R.; Der, C. J.; Barbacid, M.; Manne, V. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras-2/TC21, transformation. Oncogene 1995, 10, 1905-1913.
178. Oldham, S. M.; Clark, G. J.; Gangarosa, L. M.; Coffey, R. J., Jr.; Der, C. J. Activation of the Raf-1/MAP kinase is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6924-6928.
179. Jackson, J. H.; Li, J. W.; Buss, J. E.; Der, C. J.; Cochrane, C. G. Polylysine domain of K-Ras 4B is crucial for malignant tranformation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12730-12734.
180. James, G. L.; Goldstein, J. L.; Brown, M. S. Polylysine and CVIM sequences of KRasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 1995, 270, 6221-6226.
181. Armstrong, S. A.; Hannah, V. C.; Goldstein, J. L.; Brown, M. S. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J. Biol. Chem. 1995, 14, 7864-7868.
182. Pittler, S. J.; Flieseler, S. J.; Fisher, P. L.; Keller, R. K.; Rapp, L. M. In vivo requirement of protein prenylation for maintenance of retinal cytoarchitecture and photoreceptor structure. J. Cell Biol. 1995, 130, 431-439.
183. Gibbs, J. B.; Kohl, N. E.; Koblen, K. S.; Oraer, L. A.; Sepp-Lorenzino, L.; Rosen, N.; Anthony, N. J.; Conner, M. W.; deSolms, S. J.; Williams, T. M.; Graham, S. L.; Hartman, G. D.; Oliff, A. Farnesyl transferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat. 1996, 38, 75-83.
184. Bernhard, E. J.; Kao, G.; Cox, A. D.; Sebti, S. M.; Hamilton, A. D.; Muschel, R. J.; McKenna, W. G. The farnesyl transferase inhibitor FTI-277 radiosensitizes H-Ras transformed rat embryo fibroblasts. Cancer Res. 1996, 56, 1727-1730.
185. McKenna, W. G.; Weiss, M. C.; Endlich, B.; Ling, C. C.; Bakanauskas, V. J.; Kelsten, M. L.; Muschel, R. J. Synergistic effects of the v-myc oncogene with H-Ras on radioresistance. Cancer Res. 1990, 50, 97-102.
186. Trent, C., II; McConkey, D. J.; Loughlin, S. M.; Harbison, M. T.; Fernandez, A.; Ananthaswamy, H. N. Ras signaling in tumor necrosis factor-induced apoptosis. EMBO J. 1996, 15, 4497-5505.
187. Indolfi, C.; Awedimento, E. V.; Rapacciuolo, A.; DiLorenzo, E.; Esposito, G.; Stabile, E.; Feliciello, A.; Mele, E.; Giuliano, P.; Condorelli, G. L.; Chiariello, M. Inhibition of cellular Ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Medicine 1995, 1, 541-545.